RT Journal Article
T1 Novel Non-Invasive Quantification and Imaging of Eumelanin and DHICA Subunit in Skin Lesions by Raman Spectroscopy and MCR Algorithm: Improving Dysplastic Nevi Diagnosis.
A1 Ruiz, José Javier
A1 Marro, Monica
A1 Galván, Ismael
A1 Bernabeu-Wittel, José
A1 Conejo-Mir, Julián
A1 Zulueta-Dorado, Teresa
A1 Guisado-Gil, Ana Belén
A1 Loza-Álvarez, Pablo
K1 Raman spectroscopy analysis
K1 dysplastic nevus syndrome
K1 eumelanin
K1 melanoma
K1 multivariate analysis
K1 reactive oxygen species
K1 skin neoplasms
AB Malignant melanoma (MM) is the most aggressive form of skin cancer, and around 30% of them may develop from pre-existing dysplastic nevi (DN). Diagnosis of DN is a relevant clinical challenge, as these are intermediate lesions between benign and malignant tumors, and, up to date, few studies have focused on their diagnosis. In this study, the accuracy of Raman spectroscopy (RS) is assessed, together with multivariate analysis (MA), to classify 44 biopsies of MM, DN and compound nevus (CN) tumors. For this, we implement a novel methodology to non-invasively quantify and localize the eumelanin pigment, considered as a tumoral biomarker, by means of RS imaging coupled with the Multivariate Curve Resolution-Alternative Least Squares (MCR-ALS) algorithm. This represents a step forward with respect to the currently established technique for melanin analysis, High-Performance Liquid Chromatography (HPLC), which is invasive and cannot provide information about the spatial distribution of molecules. For the first time, we show that the 5, 6-dihydroxyindole (DHI) to 5,6-dihydroxyindole-2-carboxylic acid (DHICA) ratio is higher in DN than in MM and CN lesions. These differences in chemical composition are used by the Partial Least Squares-Discriminant Analysis (PLS-DA) algorithm to identify DN lesions in an efficient, non-invasive, fast, objective and cost-effective method, with sensitivity and specificity of 100% and 94.1%, respectively.
SN 2072-6694
YR 2022
FD 2022-02-18
LK http://hdl.handle.net/10668/20874
UL http://hdl.handle.net/10668/20874
LA en
DS RISalud
RD Apr 8, 2025